Estilo de vida y estado nutricional del adulto mayor / Life style and nutritional status of the elderly

El presente trabajo de investigación es de tipo cuantitativo, con diseño descriptivo correlacional. El objetivo fue determinar la relación que existe entre estilo de vida y estado nutricional del adulto mayor de la H.U.P Javier Heraud-Santa. La muestra estuvo constituida por 143 adultos mayores. Para la recolección de datos se utilizaron dos instrumentos: la escala de estilo de vida y la tabla de valoración nutricional según índice de masa corporal para el adulto mayor de 60 años a más. El análisis y procesamiento de datos se realizó en el Software SPSS versión 18.0. Se aplicó la prueba estadística de independencia de criterios Chi Cuadrado, con 95% de confianza, para determinar la relación que existe entre las variables, llegándose a las siguientes conclusiones: Más de la mitad de los adultos mayores presenta un estilo de vida no saludable y un menor porcentaje, saludable. En relación a estado nutricional se encontró que menos de la mitad de los adultos mayores presentan estado nutricional normal; más de la cuarta parte, sobrepeso; menos de la quinta parte, delgadez; y más de la décima parte, obesidad. No existe relación estadísticamente significativa entre el estilo de vida y el estado nutricional en el adulto mayor de la H.U.P. "Javier Heraud" del distrito de Santa.

This nonexperimental research of descriptive corelational design aimed to establish the relationship between life style and nutritional status of the elderly at Javier Heraud shanty twon-Santa. The sample considered of 143 elderly. Two were the data collection instruments used: The lifestyle sacale and the Nutritional table according to the body mass index of aged 60 and above. The SPSS versión 18.0 was used for dataprocessing. Results results were statistically analyzed by means of the Chi Square test for independence. The study came to the following conclusions: More than half of the elderly present unhealthy lifestyle while a minority present healthy one. Respect to the nutritional status less than half of the eldelry present an average nutritional status, more than one-fourth are overweight, less than one-fifth are thin and more than one-tenth are obese. There is no statistically significant relationship between lifestyle and nutritional status of the elderly at Javier Heraud shanty towm-Santa.

Effects of fexofenadine, diphenhydramine, and placebo on performance of the test of variables of attention (TOVA).

OBJECTIVE: To determine the effects of diphenhydramine 50 mg and fexofenadine 180 mg on cognitive performance using the Test of Variables of Attention (TOVA), and to ascertain whether the TOVA was sufficiently sensitive to differentiate between the effects of these first- and second-generation H1-receptor antagonists on performance. STUDY DESIGN: The study used a double-blind, placebo-controlled, randomized, crossover design. Forty-two subjects completed four separate TOVA tests: at baseline and after administration of placebo, diphenhydramine 50 mg, and fexofenadine 180 mg. On each occasion, subjects rated subjective feelings of drowsiness on a visual analog scale (VAS) before taking the TOVA. RESULTS: Compared with placebo, diphenhydramine caused an increased response time (P = 0.0230) and more omission errors (P = 0.0398). Diphenhydramine was also associated with increased drowsiness VAS ratings (P = 0.0065) compared with placebo. Diphenhydramine caused significantly more commission errors than fexofenadine (P = 0.0354). Neither placebonor fexofenadine 180 mg caused significant changes in any TOVA or VAS measurements compared with baseline. Fexofenadine was not statistically different from placebo for any evaluation. CONCLUSIONS: The TOVA was sufficiently sensitive to differentiate between the central nervous system effects of fexofenadine and diphenhydramine. Fexofenadine 180 mg had no significant effect on the TOVA measures of performance or on self-reported drowsiness compared with placebo. In contrast, diphenhydramine 50 mg caused significant increases in omission errors and response time on the TOVA and increases in self-reported drowsiness compared with placebo [corrected].

Medium and long-term growth in children receiving intranasal beclomethasone dipropionate: a clinical experience.

BACKGROUND: A 12-month controlled pediatric study of intranasal beclomethasone dipropionate (BDP) reported a 0.9 cm decrease in annual height growth velocity. Since children with allergic rhinitis may be treated for years, this report evaluates long-term height growth effects. METHODS: We reviewed the clinical charts of children with allergic rhinitis who were treated for the first time with intranasal BDP and were less than 10 years of age at initiation. Height was determined by stadiometry before intranasal corticosteroid therapy and compared with height at a final visit. RESULTS: Sixty children aged 24 to 117 months (mean age, 70 months) were treated for an average of 36 months. The pretherapy height percentile was 44.6, which increased to the 52.2 percentile at the final visit. CONCLUSIONS: Long-term clinical use of intranasal BDP in children was not associated with decreased height growth. This outcome may reflect decreased long-term compliance compared with a short-term study. However, the treatment remained effective. Some children may be at special risk. Careful height measurements are recommended every 6 months.